BETHESDA, Md.--(BUSINESS WIRE)--Dec. 20, 2005--RegeneRx Biopharmaceuticals, Inc. (AMEX:RGN) (www.regenerx.com) reported that it received the first patent in Hong Kong related to its TB4 wound healing technology platform. The patent represents technology that was exclusively licensed from the National Institutes of Health (“NIH”) in 1999 and is a key patent underlying RegeneRx’s technology platform. Similar patents have recently been issued in Australia and Europe.
